Manage episode 231202099 series 1947483
On this episode, we are joined by Brian Gilbert, PharmD, BCPS, BCCCP, David Moran, PharmD, and Jacob Reeder, PharmD, BCCCP to discuss andexanet alfa (Andexxa). We contrast the DOAC benefits that are popular among the ambulatory care community with the DOAC risks that the critical care teams often deal with. Dr. Gilbert leads the review of some concerns that many clinicians have with Andexxa.
We recently had a paper publish in the American Journal of Emergency Medicine (Dr. Gilbert was the lead author). The name of the article and link can be found below:
Throwing it in reverse: An update on reversal of oral factor Xa inhibitors
If you have any questions, reach out to us on any of the following:
Mike - email@example.com Cole - firstname.lastname@example.org
Instagram and other social media platforms - @corconsultrx
This podcast reviews current evidence-based medicine and pharmacy treatment options. This podcast is intended to be used for educational purposes only and is intended for healthcare professionals and students. This podcast is not for patients and not intended as advice or treatment.